The China National Medical Products Administration (NMPA) has approved felzartamab (Jingfei), a human monoclonal antibody targeting CD38, in combination with lenalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy, according to TJ Biopharma, the manufacturer of the drug.
The approval marks the first global regulatory clearance for felzartamab, following clinical development and registration applications successfully completed by TJ Biopharma in Greater China, according to a press release by the company.
Under an agreement reached in April 2026, Biogen acquired exclusive rights to felzartamab in Greater China. Biogen will be responsible for product commercialization, while TJ Biopharma will handle commercial drug supply through its Good Manufacturing Practice (GMP) facility in Hangzhou.
Leave feedback about this